Projects within scientific research help us in creating better therapies, so that those who suffer from scleroderma and systemic sclerosis can access proper, equitable care.
FESCA also encourages the active involvement of politicians and pharmaceutical companies, and we take part in many projects working to improve quality of life for those who have scleroderma.
Patients with systemic sclerosis who are planning a pregnancy may be interested in participating in an international observational prospective study on pregnancy in women with systemic sclerosis.
Read latest FASST newsletter on the research.
The purpose of this study is to evaluate the effectiveness and safety of IVA337 for the treatment of Diffuse Cutaneous Systemic Sclerosis.
With the help of FESCA and other contributing centers the DeSScipher project had become the largest prospective observational research project ever on systemic sclerosis!
DeSScipher is the 1st international EC-funded research project, and currently also the largest project, on the rare disease systemic sclerosis (SSc).
On the 1st April 2013 the first international EU-funded research project “DeSScipher” started!
In an effort to improve non-pharmacological care for scleroderma patients, the EUSHNet project is attempting to evaluate the existing situation in health professional practice in scleroderma across European countries.
FESCA, Federation of European Scleroderma Associations aisbl, encourages and undertake surveys, research projects and clinical trials related to the systemic sclerosis disease, and the publication of the results of any such research.
FESCA is always looking for better therapies. This is why we are partners with many different pharma companies. Pay our Scleroderma projects section a visit, and learn more about scleroderma research projects we're involved in.